AstraZeneca announced positive Phase 3 PREVAIL trial results for gefurulimab, a self-administered C5 complement inhibitor targeting generalized myasthenia gravis (gMG). Gefurulimab met primary and all secondary endpoints, offering a more convenient alternative to infused therapies. The success supports regulatory discussions and strengthens AstraZeneca's pipeline in autoimmune diseases, positioning gefurulimab as a potential blockbuster treatment to improve patient self-management and quality of life.